Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To identify proteins involved in melanoma metastasis mechanisms, comparative proteomic studies were undertaken on B16F10 and B16Bl6 melanoma cell lines and their subsequent syngenic primary tumours as pulmonary metastases were present only in the mice bearing a B16Bl6 tumour. 2DE analyses followed by MALDI-TOF identification showed variations of 6 proteins in vitro and 13 proteins in vivo. Differential expressed proteins in tumours were related to energy production and storage. Two differentially expressed proteins which had not been previously associated to melanoma progression, annexin A1 (ANXA1) and creatine kinase B (CKB), were found both in cells and in tumours. To characterize ANXA1 involvement in melanoma B16 dissemination, we reduced ANXA1 protein level by siRNA and observed a significant decrease of B16Bl6 cell invasion through Matrigel coated chambers. We further demonstrated that the presence of several formyl peptide receptors (FPR1, FPRrs1 and 2) revealed by qRT-PCR, played a role in B16 invasion: incubation of B16Bl6 cells with the FPR agonist (fMLP) or antagonist (tBOC) enhanced or decreased Matrigel coated chamber invasion respectively, with a correlation of ANXA1 levels in both treatments. As ANXA1 could bind to FPRs, this should amplify invasion and enhance melanoma dissemination.
...
PMID:Proteomic studies of B16 lines: involvement of annexin A1 in melanoma dissemination. 1895

Annexin A1 (ANXA1) is a calcium- and phospholipid-binding protein and is considered to play an important role in tumorigenesis. However, the correlation between ANXA1 expression and tumor clinicopathological features in patients with breast cancer remains unclear. This study investigated the prognostic value of ANXA1 protein as breast cancer marker. Tissue microarray blocks, containing 20 cases of non-tumor breast tissue, 20 cases of benign breast lesion and 135 cases of breast cancer (107 with lymph node metastasis), were constructed. Expression of ANXA1 in these specimens was analyzed using immunohistochemistry. In non-tumor tissue and benign breast lesions, myoepithelial cells showed strong expression of ANXA1. Negative ANXA1 expression was significantly associated with advanced disease stage (P<0.05), especially pathological-N stage (P<0.01). The patients with loss of ANXA1 expression in tumor tissues showed a significantly worse overall survival compared with positive ones (P<0.05). ANXA1 did not correlate well with estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status. Moreover, the level of ANXA1 expression in lymph node metastases was higher than corresponding primary breast cancer. These results suggest that ANXA1 may play a multifaceted role in breast cancer development, progression, and metastases.
...
PMID:Annexin A1 expression and its prognostic significance in human breast cancer. 2035 77